Skip to content

Correlation between retinal branch vein occlusion and retinal blood flow density and cytokines

Correlation between retinal branch vein occlusion and retinal blood flow density and cytokines

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100051752
Enrollment
Unknown
Registered
2021-10-02
Start date
2021-10-01
Completion date
Unknown
Last updated
2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Retinal vein occlusion

Interventions

Branch retinal vein occlusion group:None
Senile cataract group:None

Sponsors

Shanghai Tenth People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
45 Years to 75 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria for patients with BRVO: 1. Age 45-75 years old; 2. Unilateral BRVO-ME without abnormalities in the contralateral eye; 3. Initial or previous anti-VEGF therapy for more than 6 months; 4.OCTA image quality >= 5; 5. Sign informed consent; 6. Age >=18 years old at the time of signing the informed consent; 7. Ability to adhere to the study protocol. Inclusion criteria for control group: 1. Sign informed consent; 2. Age >=18 years old at the time of signing the informed consent; 3. Ability to adhere to the study protocol.

Exclusion criteria

Exclusion criteria: Patients with BRVO: 1. Patients with other ocular diseases, such as diabetic retinopathy, glaucoma, uveitis, etc., were excluded; 2. Previous history of intraocular surgery and laser photocoagulation; 3. Severe cataract or other reasons lead to refractive interstitial opacity, affecting fundus imaging; 4. High myopia; 5. Patients with severe systemic disease, vasculitis, renal, hepatic, thyroid, and cardiovascular disease. Control group: 1. Excluding senile cataract, patients with other ocular diseases, such as retinal vascular disease, age-related macular degeneration, diabetic retinopathy, glaucoma, uveitis, etc; 2. Patients with severe systemic diseases, vasculitis, renal, hepatic, thyroid and cardiovascular diseases were excluded.

Design outcomes

Primary

MeasureTime frame
Deep-superficial flow ratio ;IL-8;

Secondary

MeasureTime frame
TNF-a;IL-6;

Countries

China

Contacts

Public ContactPeng Qing

Shanghai Tenth People's Hospital

drqingpeng@126.com+86 189 1768 4853

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026